Jane Street Group LLC grew its holdings in 908 Devices Inc. (NASDAQ:MASS - Free Report) by 118.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 113,890 shares of the company's stock after acquiring an additional 61,851 shares during the quarter. Jane Street Group LLC owned about 0.33% of 908 Devices worth $251,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of 908 Devices by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 581,300 shares of the company's stock valued at $1,279,000 after acquiring an additional 13,512 shares during the last quarter. Northern Trust Corp boosted its position in shares of 908 Devices by 7.5% in the 4th quarter. Northern Trust Corp now owns 200,764 shares of the company's stock valued at $442,000 after purchasing an additional 14,087 shares during the period. Hsbc Holdings PLC boosted its position in shares of 908 Devices by 32.2% in the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after purchasing an additional 5,112 shares during the period. Prudential Financial Inc. acquired a new stake in shares of 908 Devices in the 4th quarter valued at about $34,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of 908 Devices in the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 88.06% of the company's stock.
908 Devices Trading Up 3.9%
Shares of NASDAQ MASS traded up $0.26 during trading hours on Friday, reaching $6.94. The stock had a trading volume of 451,064 shares, compared to its average volume of 1,017,142. The firm has a market cap of $248.88 million, a price-to-earnings ratio of -3.92 and a beta of 0.29. 908 Devices Inc. has a fifty-two week low of $1.81 and a fifty-two week high of $7.32. The firm has a 50-day moving average of $5.03 and a 200-day moving average of $3.54.
908 Devices (NASDAQ:MASS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. The company had revenue of $11.78 million during the quarter, compared to analysts' expectations of $11.90 million. On average, equities analysts predict that 908 Devices Inc. will post -1.99 EPS for the current year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of 908 Devices in a research report on Saturday, May 24th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.33.
Read Our Latest Analysis on MASS
Insiders Place Their Bets
In other news, CFO Joseph H. Iv Griffith sold 6,940 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $7.08, for a total value of $49,135.20. Following the completion of the sale, the chief financial officer now directly owns 102,930 shares of the company's stock, valued at $728,744.40. This trade represents a 6.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark Spoto purchased 10,000 shares of 908 Devices stock in a transaction dated Wednesday, May 14th. The stock was acquired at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the acquisition, the director now directly owns 62,971 shares in the company, valued at approximately $270,145.59. This trade represents a 18.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. 23.70% of the stock is owned by insiders.
About 908 Devices
(
Free Report)
908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.
Read More
Before you consider 908 Devices, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 908 Devices wasn't on the list.
While 908 Devices currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
